Pharmos Starts Dosing in Levotofisopam Trial

This phase 2a proof-of-concept trial is designed to assess the safety and efficacy of levotofisopam as a uric acid lowering agent in patients with gout.

Pharmos Corporation announced Tuesday the dosing of the first patients in the US using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout.

This phase 2a proof-of-concept trial is designed to assess the safety and efficacy of levotofisopam as a uric acid lowering agent in patients with gout.

This trial follows two phase 1 clinical studies that were completed by Vela Pharmaceuticals (merged with Pharmos in October 2006). In these studies, conducted in healthy volunteers in the United Kingdom and The Netherlands, levotofisopam treatment was generally well tolerated and was associated with a large and rapid reduction in serum uric acid values.